Vanda Pharmaceuticals Inc. (VNDA) has acquired U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals Ltd., a Johnson & Johnson Company. PONVORY is approved by the FDA and Health Canada to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.